Literature DB >> 8199393

Optimal management of older patients with atrial fibrillation.

W S Aronow1.   

Abstract

Long term oral warfarin should be administered to elderly patients with atrial fibrillation who are at high risk for developing thromboembolic stroke and who have no contraindications to anticoagulant therapy. Oral aspirin (acetylsalicylic acid) 325mg daily may be given to elderly patients with chronic atrial fibrillation who have contraindications to anticoagulant therapy or who are not at high risk for developing thromboembolic stroke. Management of atrial fibrillation includes treatment of the underlying disease and precipitating factors. If patients have paroxysmal atrial fibrillation with a very rapid ventricular rate associated with hypotension, severe left ventricular failure or chest pain due to myocardial ischaemia, immediate direct-current cardioversion should be performed. Intravenous verapamil, diltiazem or a beta-blocker should be used for immediate slowing of a very rapid ventricular rate associated with atrial fibrillation. If a rapid ventricular rate associated with atrial fibrillation persists at rest or during exercise despite digoxin, then oral verapamil, diltiazem or a beta-blocker should be added. Low dosages of oral amiodarone (200 to 400 mg/day) may be used in selected patients with symptomatic life-threatening atrial fibrillation refractory to other therapy. No medication which depresses atrioventricular conduction should be given to patients with atrial fibrillation and a slow ventricular rate. Cardioversion should not be performed in asymptomatic elderly patients with chronic atrial fibrillation. This author would use a beta-blocker for control of ventricular arrhythmias and following conversion of atrial fibrillation to sinus rhythm. Should atrial fibrillation recur, beta-blockers have the additional advantage of slowing the ventricular rate.

Entities:  

Mesh:

Year:  1994        PMID: 8199393     DOI: 10.2165/00002512-199404030-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  40 in total

Review 1.  Antithrombotic therapy in atrial fibrillation.

Authors:  A Laupacis; G Albers; M Dunn; W Feinberg
Journal:  Chest       Date:  1992-10       Impact factor: 9.410

Review 2.  Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients. Which is the preferred treatment?

Authors:  W S Aronow
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

3.  Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators.

Authors: 
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

4.  Preliminary report of the Stroke Prevention in Atrial Fibrillation Study.

Authors: 
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

5.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

6.  Effect of quinidine or procainamide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias.

Authors:  W S Aronow; A D Mercando; S Epstein; I Kronzon
Journal:  Am J Cardiol       Date:  1990-08-15       Impact factor: 2.778

7.  The natural history of lone atrial fibrillation. A population-based study over three decades.

Authors:  S L Kopecky; B J Gersh; M D McGoon; J P Whisnant; D R Holmes; D M Ilstrup; R L Frye
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

8.  Acebutolol in supraventricular arrhythmias.

Authors:  W S Aronow; S Van Camp; M Turbow; K Whittaker; M Lurie
Journal:  Clin Pharmacol Ther       Date:  1979-02       Impact factor: 6.875

9.  Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent.

Authors:  D David; E D Segni; H O Klein; E Kaplinsky
Journal:  Am J Cardiol       Date:  1979-12       Impact factor: 2.778

10.  Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients > or = 62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction > or = 40%.

Authors:  W S Aronow; C Ahn; A D Mercando; S Epstein; I Kronzon
Journal:  Am J Cardiol       Date:  1994-08-01       Impact factor: 2.778

View more
  1 in total

Review 1.  Cardiovascular drug therapy in the elderly: theoretical and practical considerations.

Authors:  Bradley R Williams; Jiwon Kim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.